Featured Research

from universities, journals, and other organizations

Vaccine Improves Event-free Survival For Leukemia Patients

Date:
December 11, 2007
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than nonresponders, according to researchers.

Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

Immune response to the PR1 vaccine was associated with an 8.7 month event-free survival compared with 2.4 months for non-responders. Clinical responses ranging from improvements in blood counts to complete cytogenetic remission were observed in 36 percent of the responders compared with 10 percent of non-responders.

"We did not expect dramatic responses in this clinical trial, and were pleasantly surprised to see the clinical responses and improved event-free survival" says Muzaffar Qazilbash, M.D., associate professor in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy.

The Phase I/II clinical trial that ran from 2000 to 2006 was designed to assess the vaccine's safety and its ability to elicit an immune response. Toxicity was limited to low-grade injection site side effects such as redness, swelling and some pain.

The PR1 vaccine is derived from two myeloid leukemia-associated antigens, proteins that are either overexpressed or aberrantly expressed in cancer cells. When PR1 elicits an immune response, PR1-specific cytotoxic T lymphocytes are produced that selectively kill three types of leukemia - myelodysplastic syndrome, acute myelogenous leukemia and chronic myelogenous leukemia.

Out of 66 patients in the trial, 53 had active disease and 13 were in remission when they entered the trial. Of the 53 with one of the three types of active leukemia, 25 (47 percent) had an immune response and 28 did not. Nine out of 25 responders (36 percent) had some type of clinical response compared with three of the 28 non-responders (10 percent).

Among the 13 in remission at the start of the trial, four remained in remission for a median time of 30.5 months.

In phase I trials, patients have been heavily pretreated with other therapies. "We had good accrual and a reasonably long follow-up of almost three years," Qazilbash says, "For a Phase I/II, that's a fair number of patients."

"Immunotherapy works best for low level of disease," Qazilbash says. "So patients with low leukemia burden may get the maximum benefit."

Disease-specific Phase II clinical trials of the vaccine for chronic myelogenous leukemia and myelodysplastic syndrome are planned or under way at M. D. Anderson. The Vaccine Company, which makes the PR1 vaccine, is conducting a national Phase III clinical trial for acute myelogenous leukemia.

Co-authors with Qazilbash and Molldrem are Eric D. Weider, Ph.D., Rosa L. Rios, Sijie Lu, Ph.D., Shreya Kant, Sergio Giralt, M.D., Krishna Komanduri, M.D., and Richard Champlin, M.D., all of the Department of Stem Cell Transplantation and Cellular Therapy; Peter F. Thall, Ph.D., and Xuemei Wang, of M. D. Anderson's Department of Biostatistics; and Elihu H. Estey, M.D., of Jorge Cortes, M.D., M. D. Anderson's Department of Leukemia.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Vaccine Improves Event-free Survival For Leukemia Patients." ScienceDaily. ScienceDaily, 11 December 2007. <www.sciencedaily.com/releases/2007/12/071210094351.htm>.
University of Texas M. D. Anderson Cancer Center. (2007, December 11). Vaccine Improves Event-free Survival For Leukemia Patients. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2007/12/071210094351.htm
University of Texas M. D. Anderson Cancer Center. "Vaccine Improves Event-free Survival For Leukemia Patients." ScienceDaily. www.sciencedaily.com/releases/2007/12/071210094351.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins